Edgar Filing: Sorrento Therapeutics, Inc. - Form 4

Sorrento Therapeutics, Inc. Form 4 September 04, 2013

OMB APPROVAL FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION OMB 3235-0287 Washington, D.C. 20549 Number: Check this box January 31, Expires: if no longer 2005 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF subject to Estimated average **SECURITIES** Section 16. burden hours per Form 4 or response... 0.5 Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction 1(b). (Print or Type Responses) 1. Name and Address of Reporting Person * 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading Opko Health, Inc. Issuer Symbol Sorrento Therapeutics, Inc. (Check all applicable) [OTCQB:SRNE] _X__ 10% Owner (Last) (First) (Middle) 3. Date of Earliest Transaction Director _ Other (specify Officer (give title (Month/Day/Year) below) below) 4400 BISCAYNE BLVD. 09/04/2013 (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check Filed(Month/Day/Year) Applicable Line) _X_ Form filed by One Reporting Person _ Form filed by More than One Reporting MIAMI, FL 33137 Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

· • • /	Table 1 - Non-Derivative Securities Acquired, Disposed of, or beneficiary Owned								
1.Title of	2. Transaction Date	3.	4. Securities Acquired			5. Amount of	1	ship 7. Nature of	
Security	(Month/Day/Year)	Execution Date, if		ction(A) or Disposed of			Securities	Form: Direct	Indirect
(Instr. 3)		any	Code	(D)			Beneficially	(D) or	Beneficial
		(Month/Day/Year)	(Instr. 8)	(Instr. 3, 4 and 5)		Owned	Indirect (I)	Ownership	
						Following	(Instr. 4)	(Instr. 4)	
					()		Reported		
					(A)		Transaction(s)		
					or	D.	(Instr. 3 and 4)		
			Code V	Amount	(D)				
Common Stock	09/04/2013		S	9,300	D	\$ 7.75	2,344,163	D	
Common Stock	09/04/2013		S	55	D	\$ 8.01	2,344,108	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: Sorrento Therapeutics, Inc. - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Under Secur	unt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships							
L O	Director	10% Owner Office		Other				
Opko Health, Inc. 4400 BISCAYNE BLVD. MIAMI, FL 33137	Х							
Signatures								
Juan F. Rodriguez, Sr. Vice President, CFO		09/	04/2013					
**Signature of Reporting Person			Date					
Explanation of Responses:								

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.